Tatiana V. Shelekhova

Saratov, SAR, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Results of a prospective observational study of imiglucerase biosimilar in adults with type I Gaucher disease

Results of a prospective observational study of imiglucerase biosimilar in adults with type I Gaucher disease

Journal: Terapevticheskii arkhiv

Published: January 23, 2025

Multiple myeloma: response to treatment and survival of patients according to the interim analysis of the Russian observational, retrospective-prospective, multicenter cohort study (MULTISPECT)

Multiple myeloma: response to treatment and survival of patients according to the interim analysis of the Russian observational, retrospective-prospective, multicenter cohort study (MULTISPECT)

Journal: Terapevticheskii arkhiv

Published: August 09, 2022

Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies.

Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies.

Journal: Leukemia & lymphoma

Published: October 28, 2020

Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.

Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.

Journal: BMC cancer

Published: September 29, 2020

Comparison of the clinical benefits of second-line drugs modifying the course of multiple sclerosis

Comparison of the clinical benefits of second-line drugs modifying the course of multiple sclerosis

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Published: September 15, 2020

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.

Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.

Journal: The Lancet. Oncology

Published: September 04, 2020

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.

Journal: Lancet (London, England)

Published: November 04, 2019

The relationship between oxidative stress and cytogenetic abnormalities in B-cell chronic lymphocytic leukemia.

The relationship between oxidative stress and cytogenetic abnormalities in B-cell chronic lymphocytic leukemia.

Journal: Experimental and molecular pathology

Published: June 02, 2019

The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty.

The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty.

Journal: Pharmacogenomics and personalized medicine

Published: August 14, 2018

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.

Journal: The New England journal of medicine

Published: December 13, 2017

The patterns of alteration of content of growth-stimulating and growth-inhibiting factors in blood serum under β-cell chronic lymphatic leukemia and their diagnostic value.

The patterns of alteration of content of growth-stimulating and growth-inhibiting factors in blood serum under β-cell chronic lymphatic leukemia and their diagnostic value.

Journal: Klinicheskaia laboratornaia diagnostika

Published: December 19, 2016

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Journal: The Lancet. Oncology

Published: September 23, 2014

Showing 1-12 of 13

Last Updated: 09/26/2026